159 related articles for article (PubMed ID: 33547646)
1. Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration.
Le Tilly O; Azzopardi N; Bonneau C; Desvignes C; Oberkampf F; Ezzalfani M; Ternant D; Turbiez I; Gutierrez M; Paintaud G
Clin Pharmacol Ther; 2021 Jul; 110(1):210-219. PubMed ID: 33547646
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression.
Zagouri F; Zoumpourlis P; Le Rhun E; Bartsch R; Zografos E; Apostolidou K; Dimopoulos MA; Preusser M
Cancer Treat Rev; 2020 Aug; 88():102046. PubMed ID: 32599393
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer.
Malani R; Fleisher M; Kumthekar P; Lin X; Omuro A; Groves MD; Lin NU; Melisko M; Lassman AB; Jeyapalan S; Seidman A; Skakodub A; Boire A; DeAngelis LM; Rosenblum M; Raizer J; Pentsova E
J Neurooncol; 2020 Jul; 148(3):599-606. PubMed ID: 32506369
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
[TBL] [Abstract][Full Text] [Related]
5. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
Bonneau C; Paintaud G; Trédan O; Dubot C; Desvignes C; Dieras V; Taillibert S; Tresca P; Turbiez I; Li J; Passot C; Mefti F; Mouret-Fourme E; Le Rhun E; Gutierrez M
Eur J Cancer; 2018 May; 95():75-84. PubMed ID: 29635147
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin
Quartino AL; Li H; Kirschbrown WP; Mangat R; Wada DR; Garg A; Jin JY; Lum B
Cancer Chemother Pharmacol; 2019 Feb; 83(2):329-340. PubMed ID: 30467591
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
Kumthekar PU; Avram MJ; Lassman AB; Lin NU; Lee E; Grimm SA; Schwartz M; Bell Burdett KL; Lukas RV; Dixit K; Perron I; Zhang H; Gradishar WJ; Pentsova EI; Jeyapalan S; Groves MD; Melisko M; Raizer JJ
Neuro Oncol; 2023 Mar; 25(3):557-565. PubMed ID: 35948282
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal Trastuzumab as a Potential Cause of Drug-Induced Aseptic Meningitis.
Pappa E; Conforti R; Hoang-Xuan K; Alentorn A
Can J Neurol Sci; 2019 May; 46(3):358-359. PubMed ID: 30905325
[No Abstract] [Full Text] [Related]
10. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.
Zagouri F; Sergentanis TN; Bartsch R; Berghoff AS; Chrysikos D; de Azambuja E; Dimopoulos MA; Preusser M
Breast Cancer Res Treat; 2013 May; 139(1):13-22. PubMed ID: 23588955
[TBL] [Abstract][Full Text] [Related]
11. [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
Gutierrez M; Lyazidi S; Brasseur L; Cvitkovic F; Le Scodan R
Bull Cancer; 2011 Apr; 98(4):417-24. PubMed ID: 21540147
[TBL] [Abstract][Full Text] [Related]
12. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
[TBL] [Abstract][Full Text] [Related]
13. Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report.
García FJV; Carrión NP; de la Cruz-Merino L
Medicine (Baltimore); 2020 Jan; 99(1):e18298. PubMed ID: 31895768
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis.
Mego M; Sycova-Mila Z; Obertova J; Rajec J; Liskova S; Palacka P; Porsok S; Mardiak J
Breast; 2011 Oct; 20(5):478-80. PubMed ID: 21700455
[TBL] [Abstract][Full Text] [Related]
15. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
[TBL] [Abstract][Full Text] [Related]
17. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
Li C; Agarwal P; Gibiansky E; Jin JY; Dent S; Gonçalves A; Nijem I; Strasak A; Harle-Yge ML; Chernyukhin N; LoRusso P; Girish S
Clin Pharmacokinet; 2017 Sep; 56(9):1069-1080. PubMed ID: 27995530
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
